Overview of Кейвер

Quick Facts

Property	Description
Active Ingredient	Dexketoprofen
Form	Tablets and Solution for Injection
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose	Relief of pain, inflammation, and fever
Origin	Synthetic, Propionic Acid Derivative

1. What Type of Medicine is Кейвер and What is its Class?

Кейвер is a medicinal product whose active component, Dexketoprofen, belongs to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), specifically within the group of Propionic acid derivatives. As an NSAID, the drug is designed to provide symptomatic relief rather than addressing the root causes of disease.

Dexketoprofen provides analgesic, anti-inflammatory, and antipyretic effects. This indicates the medicine is clinically recognized for simultaneously easing pain, reducing swelling, and bringing down high temperatures. The drug is frequently used in scenarios where quick relief from acute pain is necessary.

2. What is the Composition of Кейвер and its Origin?

The chemical foundation of Кейвер is Dexketoprofen trometamol, a compound created through a synthetic process. Dexketoprofen is the active S-(+)-enantiomer of the drug ketoprofen. This means it is a purified, more targeted version of a related substance.

The inclusion of the trometamol salt in the formulation is a distinguishing feature, as it enhances the drug's solubility. This characteristic promotes rapid absorption into the body, which is essential for a fast onset of action in acute pain settings. Since it contains only one active ingredient, Кейвер is defined as a monopreparation.

3. In What Forms is Кейвер Available?

Кейвер is supplied in two primary physical forms to accommodate different patient needs. These include film-coated tablets for oral intake, and an aqueous solution packaged in ampoules for parenteral (injectable) delivery. The availability of both forms ensures flexible application for patients, covering both standard and acute care settings.

What side effects are possible with Кейвер?

Possible Side Effects and Safety Information for Кейвер

Key Safety Warnings and Adverse Reactions

Use of Кейвер (Ketoprofen) is associated with adverse reactions that are classified by frequency and System-Organ Class. The most common adverse reactions reported involve the gastrointestinal (GI) tract, including dyspepsia, nausea, abdominal discomfort, and diarrhea. Headache, dizziness, and somnolence are also commonly reported.

Classification	Serious Adverse Reactions (Potential for Fatal Outcome)
Cardiovascular Risk	Increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with prolonged use and is generally contraindicated for perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Risk	Increased risk of serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can occur without warning symptoms and are a major safety concern, particularly in the elderly.
Severe Reactions	Potential for severe dermatological reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), serious allergic (anaphylactic) reactions, and significant hepatic/renal dysfunction.

Population-Specific Safety Considerations

Pregnancy: The medication is generally contraindicated during the third trimester of pregnancy due to documented risks of premature closure of the fetal ductus arteriosus and renal dysfunction. Use during the first two trimesters requires caution.
Elderly Patients: Older individuals are at a significantly increased risk for serious adverse events, especially severe gastrointestinal bleeding and renal impairment.

Safety Restrictions and Patterns

The incidence and severity of certain adverse effects, particularly GI and cardiovascular events, are generally considered to be dose-dependent and increase with the duration of treatment. The drug is contraindicated in patients with active peptic ulcers, severe heart failure, or a history of significant allergic reactions to aspirin or other NSAIDs.

Overdose and Emergency Response

Overdose manifestations for the NSAID Dexketoprofen are officially documented to include gastrointestinal symptoms such as nausea, vomiting, and pain in the upper stomach area. Central nervous system effects like drowsiness, lethargy, headache, and confusion are also commonly reported signs of toxicity.

Following very large ingestions, severe, potentially life-threatening systemic outcomes may occur, including respiratory depression, coma, convulsions, and acute renal failure. Additionally, regulatory documents note the risk of severe gastrointestinal bleeding, hypotension, and hypertension as serious physiological effects.

Immediate medical attention is required for any suspected large overdose. Furthermore, patients must seek emergency help at once if they experience symptoms indicative of a severe cardiovascular event, such as chest pain, sudden weakness or numbness, trouble breathing, or slurred speech, as mandated for the NSAID class.

Management is officially limited to symptomatic and supportive care because no specific antidote is known. Gastric decontamination, such as administering activated charcoal, may be indicated for recent ingestions or large amounts. Regulatory warnings specifically note that elderly patients face an increased risk of serious gastrointestinal complications, and children may experience convulsions in overdose situations. Procedures like hemodialysis are cited as unlikely to be effective due to the high protein binding of the active substance.

Therapeutic Uses of Кейвер

What Кейвер Treats: Main Uses and Benefits

The medicine is relevant when supportive symptom management is appropriate for acute, distressing manifestations across several medical domains. Its application is considered relevant in contexts involving heightened systemic burden, such as managing acute discomfort.

Кейвер is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort and swelling that may create noticeable physiological strain. The medicine is commonly used to help with multiple symptom clusters that appear simultaneously, including acute pain in conditions such as musculoskeletal injuries, dental procedures, and menstrual pain (dysmenorrhea). The medicine is commonly used to help with symptomatic relief during difficult episodes of acute pain and inflammation.

This supportive relief, often needed when short-term symptomatic assistance is required, may assist with maintaining functional stability. The application may assist with coping more steadily with difficult episodes and supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Discomfort
Relevant Therapeutic Area	Acute pain and inflammatory states
Symptom Benefit	Simultaneous easing of pain, inflammation, and fever
Typical Context	Post-injury, post-procedure, or episodic flares

Eligibility and Restrictions for Use

The eligibility for using Кейвер (Dexketoprofen) is defined by regulatory bodies based on age, pre-existing conditions, and physiological status. The medicine is sanctioned for adult patients (generally 18 years of age).

Category	Eligibility Classification
Populations for whom use is allowed	Adults (18 years and older).
Populations for whom use is not recommended	Children and Adolescents (< 18 years); Pregnant women (first and second trimesters); Breastfeeding women.
Populations for whom use is contraindicated	Patients with severe heart failure, severe hepatic dysfunction (Child-Pugh 10-15), or moderate to severe renal dysfunction (Creatinine Clearance leq 59 mL/ min).

Official Eligibility Statements:

Use is contraindicated in patients with active peptic ulcer/GI haemorrhage, a history of recurrent GI bleeding, or those who experience asthma attacks from other NSAIDs.
The medicine is contraindicated during the third trimester of pregnancy due to risk of fetal harm.
Older adults are permitted to use the medicine but must be started at the lowest recommended dose and closely monitored.
Safety and efficacy have not been established in the pediatric population; therefore, use is not recommended in children and adolescents.

These eligibility rules define clear limitations by strictly excluding patients with severe organ impairment or high bleeding risk, while restricting use in populations with insufficient safety data or physiological vulnerability.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Кейвер (Dexketoprofen) highlights specific interaction patterns across pharmacodynamic and pharmacokinetic mechanisms. Co-administration is formally not recommended or must be avoided with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including high-dose Acetylsalicylic acid (Aspirin), due to a significantly increased risk of severe gastrointestinal bleeding and ulceration. Use with Anticoagulants (e.g., Warfarin, Heparins) is restricted as it increases the risk of hemorrhage by interfering with haemostasis.

Certain substances have their plasma concentrations altered. Dexketoprofen reduces the renal clearance of Lithium and high-dose Methotrexate, causing an official elevation of their plasma levels and potential toxicity. Similarly, Probenecid reduces Dexketoprofen's plasma clearance, increasing its systemic exposure. No mandatory timing separation rules are formally documented.

Interaction Category	Official Regulatory Statement
Antihypertensives	May diminish the efficacy of Diuretics, ACE-inhibitors, and ARBs, and increase the risk of renal failure (nephrotoxicity).
GI Risk Enhancers	Oral Corticosteroids and Antiplatelet Agents increase the incidence of gastrointestinal bleeding and ulceration.
Substance Interaction	Alcohol consumption is officially not recommended due to enhanced GI bleeding risk.
Population Caution	Caution is noted for the elderly and patients with dehydration due to an amplified risk of interaction-related nephrotoxicity.

Mechanism of Action

Targeted Inhibition of the Cyclooxygenase Enzyme System

The primary mechanism of Кейвер (Dexketoprofen) is defined by the reversible, non-selective inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This action initiates the central cascade by blocking the conversion of Arachidonic Acid into prostaglandins, which are lipid mediators of inflammatory and nociceptive signaling pathways.

Modulation of Nociceptive and Thermoregulatory Signaling Pathways

By reducing prostaglandin synthesis, the drug's mechanism produces two distinct physiological consequences: it prevents the over-sensitization of peripheral nociceptors (pain receptors), thereby modulating nociceptive signaling by inhibiting peripheral sensitization. Simultaneously, it modulates hypothalamic activity in the central nervous system, effectively resetting the elevated body's temperature set-point. This dual action modulates activity within the inflammatory and thermoregulatory pathways.

Constraint of a Reversible, Mediator-Dependent Mechanism

This mechanistic domain is relevant because the effect profile is inherently constrained by the mechanism's functional limitations. Since the COX inhibition is reversible, the duration of the physiological effects is directly dependent on maintaining a sufficient concentration of the active molecule at the enzyme binding sites, reflecting the mechanism's reversible nature.

Dosage and Administration Information

How to Use Кейвер

Кейвер (Dexketoprofen) is utilized for short-term symptomatic relief. The medicine is provided in two main forms to accommodate different clinical needs: film-coated tablets for oral administration and a solution for parenteral use, delivered either intramuscularly (IM) or intravenously (IV).

Standard Dosing and Administration

Administration Route	Standard Adult Regimen	Maximum Daily Dose	Official Timing Instruction
Oral Tablets (25 mg)	25 mg every 8 hours, or 12.5 mg every 4–6 hours	75 mg	Taken 30 minutes before meals
Parenteral Solution (50 mg/2mL)	50 mg every 8–12 hours	150 mg	IV infusion over 10–30 minutes

The oral tablets are intended for short-term use only, limited to the duration of acute symptoms. The specific pre-meal timing for tablets is a procedural instruction intended to facilitate rapid drug absorption and onset of action.

Duration and Population Constraints

Administration of the parenteral solution is generally restricted to the initial acute symptomatic period, often not exceeding two days, with a switch to the oral form required as soon as possible.

Dose reductions apply to specific populations. For older adults, the starting total daily dose is typically reduced to 50 mg (for both oral and parenteral routes). A reduced maximum daily dose of 50 mg is also required for patients with mild renal or hepatic impairment. Furthermore, the safety and efficacy of the medicine are not established for use in children and adolescents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Кейвер (Dexketoprofen)

Evidence for Acute Pain Management

The research for Кейвер (Dexketoprofen) has primarily been studied for use in conditions characterized by acute or disruptive episodes of pain. The evidence base is largely constructed from a substantial number of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to monitor outcomes related to physical discomfort in a controlled manner, often comparing the compound to a placebo or another active analgesic.

Research was extensively applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns. Investigators studies monitored several short-term symptom axes, including pain intensity measured on standardized scales and the time elapsed until patients reported an onset of change in physical discomfort. Findings describe patterns observed in the studies where changes were measured in reported pain levels over the first few hours following administration. Research provides insight into short-term changes in pain and contributes to the broader evidence landscape.

Evidence for Menstrual Pain (Dysmenorrhea)

Research has also explored the role of Dexketoprofen was studied for use in conditions associated with acute or disruptive episodes of pain, specifically dysmenorrhea (menstrual pain). This research included specific Randomized Controlled Trials (RCTs) that often compared the drug to placebo and other medications relevant for this type of periodic discomfort.

These trials were conducted during periods of increased symptom activity, with research applied in studies examining patient-reported experiences of outcomes capturing phases of heightened symptom activity. Studies monitored how symptoms evolved in the observed populations, with results reporting patterns in pain reduction scores measured at very short time intervals.

Long-Term Research and Duration of Follow-up

The overwhelming majority of official research for Dexketoprofen, especially the high-quality Randomized Controlled Trials (RCTs), is concentrated on research exploring short-term symptom changes and single-dose administration. This means that the follow-up durations were limited, typically lasting only a few hours to a few days. As a result, long-term effects are not fully established. There is limited information for long-term outcomes such as durability of observed outcomes related to physical discomfort, or the maintenance of functional stability over months or years.

Areas Where Research is Still Needed

While research has established a framework for understanding short-term outcomes, several areas of uncertainty remain. Long-term effects are not fully established, and there is a clear research gap concerning what is known about repetitive use or for conditions that require treatment beyond a few days. Data for certain groups remain insufficient, including large-scale evidence for older adults or those with complex comorbid conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Кейвер (FAQ)

Q: Is there a risk of addiction to Keyver?

According to official regulatory documents, Кейвер (Dexketoprofen) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not designated as a controlled substance and therefore does not carry official warnings regarding physical dependence, abuse, or addiction risks associated with substances like opioids.

Q: Is Keyver sold by prescription or over the counter?

The regulatory classification of Кейвер, specifically whether it requires a prescription, varies depending on the country and the drug's formulation or dosage strength. The final determination of its access status (prescription-only or over-the-counter) is set by local health authorities.

Q: Can Keyver be taken with vitamins or supplements?

Official drug interaction data mainly focuses on interactions with prescription and over-the-counter medicines. There are no specific universal regulatory warnings against all vitamins or general supplements. However, official safety information advises caution if a supplement is known to affect blood clotting or liver function, as interactions with NSAIDs are possible.

Q: If I miss a dose of Keyver, should I take a double dose?

Official patient guidance for missed doses of Кейвер and similar medications advises against taking a double dose to make up for the one you missed. Official guidance indicates that proceeding with the next scheduled dose at the usual time is the standard approach to help avoid exceeding the daily limit.

Q: How does Keyver differ from other popular drugs in the same group?

Кейвер contains the active ingredient Dexketoprofen, which is a purified, single component (the S-(+)-enantiomer) of a related substance called Ketoprofen. This specialized chemical structure is noted in official sources as the S-(+)-enantiomer, which is linked to its analgesic effects.

Q: Why do doctors sometimes prescribe Keyver instead of Ibuprofen or Diclofenac?

Regulatory information states that Кейвер is indicated for the short-term symptomatic treatment of acute pain. Its chemical composition, often including the trometamol salt, promotes rapid absorption into the body. This characteristic facilitates a fast onset of action, which is a key physical property described in regulatory information.

Q: Can Keyver affect blood test results?

Official adverse reaction reports indicate that Кейвер may cause changes in certain laboratory tests. These changes can include elevated liver enzymes (transaminases) and blood urea nitrogen (BUN). Official data indicates the medication may also influence the results of blood clotting tests.

Q: Does Keyver interact with birth control pills?

Regulatory labels for NSAIDs sometimes include a warning that they may potentially reduce the effectiveness of some types of oral contraceptives. Regulatory warnings mention that patients using oral contraceptives should be aware of this potential, as official information indicates a possibility for a diminished contraceptive effect.

Q: What should I do if the effect of Keyver seems weak?

Official labeling defines the maximum daily dosage and emphasizes that the drug is for short-term treatment only. If the medication is not providing sufficient relief, official labeling states that the maximum daily limit defined in the documentation must not be exceeded.

Q: Can Keyver tablets be split in half?

The ability to split Кейвер tablets is determined by the specific product's design, which is detailed in the official product information. If the tablets feature a score-line (a dividing mark), they are typically safe to divide. If the tablets are not scored, official documentation generally states that the product is intended to be swallowed whole.

Q: Is there data on Keyver’s effect on the ability to drive?

Yes. Regulatory safety documents advise that Кейвер can cause central nervous system side effects such as dizziness, somnolence (drowsiness), and visual disturbances. Official regulatory documents indicate that the ability to drive or operate machinery may be temporarily impaired, especially when starting treatment.

Q: What are the special considerations for taking Keyver with diabetes?

While diabetes is not a direct contraindication, patients with this condition may have associated kidney or heart issues. NSAIDs are noted in official warnings as requiring caution in these groups due to a potential risk of fluid retention and possible elevation of blood pressure.

Q: Are there special instructions for Keyver for vegetarians or people with lactose intolerance?

The oral tablet formulations of Кейвер often contain lactose, which is listed in the official excipients section. Regulatory information notes that patients with certain hereditary conditions related to galactose intolerance or lactase deficiency are generally excluded from using the oral tablets.

Q: Do official documents contain information on Keyver overdose?

Yes, regulatory documents detail the reported symptoms of an overdose. These symptoms are generally consistent with major NSAID side effects, primarily affecting the gastrointestinal tract (such as vomiting and abdominal pain) and the central nervous system (including drowsiness and disorientation).

Q: Can Keyver interact with thyroid medication?

Specific interactions with thyroid hormone replacement drugs are not universally listed across official labels. However, because Кейвер is metabolized in the liver, official guidance highlights that potential interactions affecting drug clearance and plasma levels may exist, especially when taking multiple chronic medications.

Q: Does Keyver affect vision or hearing?

The official regulatory list of adverse reactions includes possible effects on both senses, though they are typically reported as uncommon. Specifically, visual disturbances and tinnitus (a ringing or buzzing in the ears) are noted as potential side effects.

How should Кейвер be stored and disposed of?

How to Store and Dispose of Dexketoprofen Trometamol

The storage of this medicine is defined by official regulatory requirements to ensure stability and safety. All forms of the product must be kept out of the sight and reach of children.

Storage Conditions

Oral forms (tablets) should not be stored above 30 C and must be kept in the outer carton for light protection.

The solution for infusion requires specific handling: dilution must be performed aseptically, and the diluted solution must be protected from natural daylight. This diluted solution remains stable for 24 hours at 25 C when light-protected.

Disposal

Any unused or expired product must be disposed of in accordance with local requirements. Medicines should not be disposed of via wastewater or household waste.

Кейвер